Dr. John Cush RheumNow
3 years 11 months ago
Can you use the BASDAI in Pregnancy?
Dr. Eric Dein ( @ericdeinmd) discusses abstract 0374 presented at #ACR22 Convergence in Philadelphia, PA. Abstract 0374: The BASDAI Index During Pregnancy.
https://t.co/UB8ZGyQ6mz https://t.co/tkr6cOIMD9
Dr. John Cush RheumNow
3 years 11 months ago
Vaccine Efficacy in Patients with Seronegative SpA
Vaccine efficacy remains an important topic at #ACR22 given the ongoing COVID-19 health crisis, current influenza season, and recently published 2022 ACR guidelines.
https://t.co/2PHrJYV8Om
Written by Dr. Sims ( @DrCassySims) https://t.co/hUFnPIDzUU
Dr. John Cush RheumNow
3 years 11 months ago
Can we accurately capture disease activity in pregnant patients with AS?
Dr. Aurelie Najm ( @AurelieRheumo) discusses Abstract 0374. #ACR22
https://t.co/oafV1BP91X https://t.co/wMelZm5iOj
Dr. John Cush RheumNow
3 years 11 months ago
Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar
Dr. Julian Segan ( @JulianSegan) discusses Abstract 1425 at #ACR22
Abstract 1425: Treatment Persistence and Switching Patterns of AMGEVITA® in German Patients with RD
https://t.co/MpNnrqYxGJ https://t.co/Sfi1kxOXLX
Dr. John Cush RheumNow
3 years 11 months ago
Fat and bone are never alone: osteoporotic fracture in RA
Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis
https://t.co/4IrdQBq1z2 https://t.co/2HySVG1SGY
Dr. John Cush RheumNow
3 years 11 months ago
Topic Podcasts #ACR22 - SpA Part3
-Opioids and Health Care Utilization in PsA and AS
-Reproductive health in a post-Roe world
-SpA: Novel Therapies, Diagnostic Dilemmas and Depression
-Tapering TNFi in nonradiographic AxSpA
and more
https://t.co/hXPlQaxPWs https://t.co/2SRYS6EOr7
There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.
Dr. John Cush RheumNow
3 years 11 months ago
How Underweight Women Can Reduce Hip Fracture Risk
https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS
Dr. John Cush RheumNow
3 years 11 months ago
Tyk2 Inhibition Effective in SLE
Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients.
https://t.co/cpbDnkfUIS https://t.co/xct8dACBAY
Dr. John Cush RheumNow
3 years 11 months ago
RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evobrutinib(861) or placebo(271) for ~ 6 mos. No diff in TEAEs or EAIR , 2 deaths (SLE), SIE 2-3/100PY https://t.co/4HOTKuCAUi https://t.co/u7KSD6RN4q
Dr. John Cush RheumNow
3 years 11 months ago
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/ufYcnuMI2r https://t.co/cOPIUpwpHf
Dr. John Cush RheumNow
3 years 11 months ago
JAMA - Update/Review of Hemochromatosis Dx and Rx.
- 5 gene defects in hepcidin. 95% HFE & the C282Y variant
- 90%are asymptomatic
- Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative
- Untreated, 9% risk of cirrhosis
https://t.co/nuq8Ioralk https://t.co/djwlVsIk3b
Dr. John Cush RheumNow
3 years 11 months ago
#ACR22 - SpA Part2
-Comorbidities in Ankylosing Spondylitis
-Early Diagnosis of AxSpA
-Fertility issues in SpA
-Gender in AxSpa
-Inadequate Dosing of HCQ Leads to Hospitalizations in SLE
-JAK inhibitors in RD
-Opioid use in PsA and SpA
https://t.co/1xJzSmekR2 https://t.co/kxpLGi8Ky4
ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways.
